Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
PIM2 encodes a protooncogene that acts as a serine/threonine protein kinase. Additionally we are shipping Proto-Oncogene Pim-2 (Serine Threonine Kinase) Proteins (18) and Proto-Oncogene Pim-2 (Serine Threonine Kinase) Kits (14) and many more products for this protein.
Showing 10 out of 130 products:
Human Polyclonal PIM2 Primary Antibody for ICC, IF - ABIN4345625
Santio, Vahakoski, Rainio, Sandholm, Virtanen, Prudhomme, Anizon, Moreau, Koskinen: Pim-selective inhibitor DHPCC-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasion. in Molecular cancer 2010
Show all 2 Pubmed References
Human Polyclonal PIM2 Primary Antibody for ELISA, WB - ABIN4345627
Morishita, Katayama, Sekimizu, Tsuruo, Fujita: Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. in Cancer research 2008
Human Polyclonal PIM2 Primary Antibody for ELISA, WB - ABIN4345628
Hammerman, Fox, Cinalli, Xu, Wagner, Lindsten, Thompson: Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation. in Cancer research 2004
Human Polyclonal PIM2 Primary Antibody for IHC (p), IP - ABIN392442
Pogacic, Bullock, Fedorov, Filippakopoulos, Gasser, Biondi, Meyer-Monard, Knapp, Schwaller: Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. in Cancer research 2007
Inhibition of the Pim1 (show PIM1 Antibodies) oncogene (show RAB1A Antibodies) results in diminished visual function.
Inhibition of PIM2 attenuated asthma symptoms and increased expression levels of interleukin (IL)10 (show IL10 Antibodies) and forkhead box (show FOXO Antibodies) protein 3 (show HSPB3 Antibodies) (FOXP3 (show FOXP3 Antibodies)) in bronchoalveolar lavage fluid.
data suggest that PIM1 (show PIM1 Antibodies)/2 kinase overexpression is a common feature of male reproductive organs tumors, which provoke tissue alterations and a large inflammatory response that may act synergistically during the process of tumorigenesis.
show that PIM1 (show PIM1 Antibodies) contributes to melanoma cell proliferation and tumor growth in vivo; however, the presence of PIM2 and PIM3 (show PIM3 Antibodies) could also influence the outcome.
the elevated expression of PIM2 in blastic cells is associated with poor prognosis of AML (show RUNX1 Antibodies) patients and their resistance to induction therapy.
Our data provide evidence for a novel role for Pim2 in the regulation of the DNA damage response (DDR (show DDR1 Antibodies)). Knockdown of Pim2 upregulates several downstream DDR (show DDR1 Antibodies) markers, mimicking the effects of doxorubicin (Dox) treatment of MM cells, and suggesting a role for the kinase as a negative regulator of this pathway.
These results demonstrate the involvement of PIM (show PIM1 Antibodies) kinases in LIF (show LIF Antibodies)-induced regulation in different trophoblastic cell lines which may indicate similar functions in primary cells.
PIM (show PIM1 Antibodies) kinases in classical Hodgkin lymphoma exhibit pleiotropic effects, orchestrating tumor immune escape and supporting Reed-Sternberg cell survival.
High PIM2 expression is associated with osteosarcoma.
We show that Pim2 inhibitors and proteasome inhibitors, such as bortezomib, have additive effects to inhibit the growth of myeloma cells, suggesting that Pim2 could be an interesting target for the treatment of multiple myeloma.
PIM2 gene knockdown enhances the anti-proliferative effect of AZD1208 in non-Hodgkin lymphoma cell line.
studies define a pathway for limiting the regulation of Foxp3 (show FOXP3 Antibodies) function because the Pim-2 kinase represents a potential therapeutic target for modulating the Treg cell suppressive activities in controlling immune responses
Pim2 facilitated allograft rejection primarily by modulating the apoptosis of effector T cells and the function of regulatory T cells.
Loss of PIM2 is associated with abnormal hematopoietic phenotypes.
signals from IL-7 (show IL7 Antibodies) and RAG DSBs activate distinct Pim (show PIM1 Antibodies) kinase family members that have context-dependent activities in regulating pre-B cell proliferation and survival.
Targeting cap-dependent translation blocks converging survival signals by AKT (show AKT1 Antibodies) and PIM 1 (show PIM1 Antibodies), 2 kinases in lymphoma
PIM2 controls the expression of the pro-inflammatory cytokine IL-6 (show IL6 Antibodies).
results support the hypothesis that Pim2, which is also a known target of Flt3 (show FLT3 Antibodies)-ITD (another gene that cooperates with PML (show PML Antibodies)-RARalpha (show RARA Antibodies)), cooperates with PRalpha to induce acute promyelocytic leukemia (show PML Antibodies)-like disease
Pim-2 is a direct link between growth factor-induced transcription and a novel, kinase-dependent pathway that promotes cell-autonomous survival
pim-2 functions similarly to pim-1 (show PIM1 Antibodies) as a pro-survival kinase; BAD is a legitimate PIM-2 substrate
Pim-2 and Akt-1 (show AKT1 Antibodies) are critical components of overlapping but independent pathways, either of which is sufficient to promote the growth and survival of nontransformed hematopoietic cells
This gene encodes a protooncogene that acts as a serine/threonine protein kinase. Studies determined the encoded protein functions to prevent apoptosis and to promote cell survival.
, proviral integration site 2
, serine/threonine-protein kinase Pim-1
, serine/threonine-protein kinase pim-2
, proto-oncogene Pim-2 (serine threonine kinase)
, serine/threonine protein kinase pim-2
, serine/threonine kinase